Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 100 people enrolled
- Started
- 6 Jun 2022
- Ended
- 28 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Metagenomic Deep Sequencing (MDS)
- Standard of Care (SOC)
- Record updated
- 26 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Presumed infectious anterior uveitis, or intermediate uveitis, or posterior uveitis, or panuveitis
- Presumed post-operative endophthalmitis
- Unilateral or bilateral
- 18 years and older
Who cannot take part
- Age < 18 years of age
- Insufficient specimen for MDS
- Pregnancy
- Unable to consent
Where in United States
- University of California, San Francisco (UCSF)San Francisco, United States
About the trial
What the trial wants to find out
This is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility criteria will be randomized to receive MDS testing results or not to receive MDS testing results. All patients will receive standard-of-care testing to guide management. Enrolled patients will be followed at week 2, week 3-6 (randomization visit), and at 4 weeks after the randomization visit. The proportions of patients who received the appropriate therapy and the proportions of patients with improved outcome will be compared between arms. Patient quality of life, MDS performance, and the provider certainly of belief will be collected.
The 2 groups in the trial
- Standard of CareExisting treatment, for comparison
Patients enrolled in the trial and randomized to the standard of care (SOC) arm will undergo standard of care testing.
Treatment: Standard of Care (SOC)
- MDSTreatment being tested
Patients enrolled in the trial and randomized to the MDS arm will undergo standard of care testing and MDS testing.
Treatment: Metagenomic Deep Sequencing (MDS)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 June 2026